|
Virtual Meetings 2020
Meet The Professor: Management of Chronic Lymphocytic LeukemiaFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee Prof John G Gribben, MD, DSc, FMedSci Chair of Medical Oncology Barts Cancer Institute Queen Mary University of London Charterhouse Square London, United Kingdom Brian T Hill, MD, PhD Director, Lymphoid Malignancy Program Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio Nitin Jain, MD Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Brad S Kahl, MD Professor of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St Louis, Missouri Anthony R Mato, MD, MSCE Associate Attending Director Chronic Lymphocytic Leukemia Program Memorial Sloan Kettering Cancer Center New York, New York John M Pagel, MD, PhD Chief of Hematologic Malignancies Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle, Washington Kerry Rogers, MD Assistant Professor in the Division of Hematology The Ohio State University Columbus, Ohio Jeff Sharman, MD Willamette Valley Cancer Institute and Research Center Medical Director of Hematology Research US Oncology Eugene, Oregon Tanya Siddiqi, MD Associate Professor Director, Chronic Lymphocytic Leukemia Program Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte, California Mitchell R Smith, MD, PhD Professor of Medicine Associate Center Director for Clinical Investigations Director, Division of Hematology and Oncology GW Cancer Center Washington, DC William G Wierda, MD, PhD DB Lane Cancer Research Distinguished Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Jennifer Woyach, MD Professor Division of Hematology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus, Ohio SERIES MODERATOR Neil Love, MD Research To Practice Agenda
Module 1: Optimal Integration of Venetoclax and BTK Inhibitors into the Front-Line Setting Module 2: Management of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Dr Wierda has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Davids — Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Dr Flinn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seagen Inc, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seagen Inc, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc. Prof Gribben — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, MorphoSys, Novartis; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Hill — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Novartis; Contracted Research: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Takeda Oncology. Dr Jain — Advisory Committee and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics SA, Aprea Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cellectis, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Precision BioSciences, Servier; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc. Dr Kahl — Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation. Dr Mato — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Octapharma, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc. Dr Pagel — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene, Gilead Sciences Inc, Takeda Oncology. Dr Rogers — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Travel: AstraZeneca Pharmaceuticals LP. Dr Sharman — Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc. Dr Siddiqi — Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Smith — Advisory Committee: AbbVie Inc, Janssen Biotech Inc; Contracted Research: Karyopharm Therapeutics; Speaker's Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma, Kite, A Gilead Company. Dr Woyach — Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Commercial Support These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP. |